UroGen registers Phase 1 dose-escalation trial of UGN-501 in recurrent NMIBC
UroGen Pharma listed a new Phase 1 study of oncolytic virus UGN-501 in bladder cancer patients, not yet recruiting.
The week's sole update for UroGen Pharma is the registration of a new early-stage trial.
- UGN-501, described in the record as a chimeric oncolytic adenovirus, administered intravesically in participants with recurrent NMIBC1, is the subject of a new Phase 1, open-label, dose-escalation study sponsored by UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. The study's status is "not yet recruiting," with an estimated enrollment of 30 participants and an estimated start date of 2026-09-30. The trial's stated purpose is to evaluate the safety and tolerability of UGN-501 administered intravesically in adult participants with recurrent non-muscle invasive bladder cancer (NMIBC) and to determine the recommended Phase 2 dose (RP2D)1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.